Comunicación Nº: 064 English version English version

¿Induce la terapia hormonal cambios histológicos en la próstata?

Ana de la Fuente, I. Antón, J.A. Ortiz, F. Sacristan, D. Pesquira, E. Zungri.

[Título] [Introducción] [Material y Métodos] [Resultados] [Iconografía] [Discusión]




1. AYALA, A.G; RO,J.Y.;BABAJAN,R.;TRONCOSO,P.AND GRIGNON,D.J: The Prostatic Capsule: Does it exist? Am J.Surg.Pathol 1989; 13(1): 21-27.

2. BANDHAUER,K.AND SPIERLER,P: The value of Cytology for the Follow-up Prostatic Cancer after Hormone and Iradiation Therapy. Eur.Urol 1985; 11:224-227.

3. BYAR,D.P:The Veterans Administration Cooperative Urological Research Group’s studies of Cancer of the Prostate. Cancer 1973; 32:1126-1131.

4. BOUDREAUX,D.; NOVICKI, D.E.; AND AIRHART,R.A: A review of the Gleason Grading System for Prostatic Adenocarcinoma and Its Clinical Application. Lessau 39. vol. VI - 1987.

5. BRAWN,P.N.; AYALA,A.G.; VON ESCHENBACH,A.C.; HUSSEY,D.H.; AND JOHNSON,D.E: Histologic Grading Study of Prostate Adenocarcinoma; The Development of a New System and Comparison with Other Methods- A Preliminary Study. Cancer 1982; 49: 525-532.

6.CRAWFORD,D.;EISENBERGER,M.A.;MC.LEOD,D.G.;SPAULDING,J.T.;BENSON,R.; DORR,F.A: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N.Engl.J.Med.1989; 313: 419-424.

7. COFFEY,D.S.AND ISSACS,J.T: Prostate Tumor Biology and cell Kinetics-Theory.Urology (Supple.March) 1981; 17: 40-53.

8. COFFEY,D.S.AND ISSACS,J.T: Control of Prostate Growth. Urology (Suppl. March) 1981;17:17-24.

9. DE LA MONTE, S.M.; MOORE,G.W.AND HUTCHINS, G.M:Metstasic Behavior of Porstate Cancer. Cancer 1986:58: 985-993.

10. DE VOOGT,H.J.;SMITH, PH.;PAVONE,M.;DE PAUW, M.;SUCIN,S.AND MEMBERS OF EORTC: Cardiovascular side effects of Diethyls tiltbestrol, Cyproterona Acetate, Medroxy progesterone acetate and Estramustine Phosphate use for the treatment of advanced prostatic cancer. J.Urol. 1986; 135: 303-307.

11. GLEASON.P.; MELLINGER.G. AND VACURG : Prediction of prognosis for prostatic adenocarcinoma by combined histological greading and clinical staging. J.Urol. 1974; 111: 58-64.

12. HUGGINS C. AND HODGES, C.V: Studies of prostatic Cancer Effect of Castration, estrogen and androgen injections of serum phosphatases in metastasic carcinoma of the Prostate. Cancer Res. 1941; 1: 293-298.

13. ISSACS,J.T.; ISSACS, W.B. AND COFFEY,D.S.: Models for development of nonreceptor methods for distinguishing androgen sensitive and insensitive prostatic tumors. Cancer Res. 1979; 39: 2652-2657.

14. KASSEY, N. Y AND NERI, O: Flutamide in advanced cancer of the prostate. Clin . Pharmacol. Ther. 1982; 31: 238-241.

15. LABRIE.F: A new approch in the hormonal treatment of prostatic cancer . complete instead of partial blockade of androgens. Andrology 1984; 7: 1-4.

16. LABRIE,F.; DUPONT,A. ET BELANGER,A: LH-RH anlogues in prostatic cancer. Lancet 1986. Feb.;22 : 445-446.

17. LEISTENSCHNEIDER, W. AND NAGEL, R: Cytological and DNA-Cytophotometric monitoring of the effect of therapy in conservatively treated Prostatic Carcinoma. Scand.J. Urol . Nephrol. Suppl. 1980; 55: 197-204.

18. LOCK,M.T.;DE JONG, F.H.;CHADHA, D.R.; SCHÖEDER, F.H: Long Term effects of Buserelin on plasma testosterone and luteinising hormone concentrations. The Lancet. 1985. Nov; 30: 1236-1237.

19.MAI,K.T.;COMMONS,A.S.; PERKINS,D.G.;YAZDI,H.M.AND COLLINS,J.P: Absence of Serum prostate-specific antigen and loss of tissue inmunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy; a report of two cases. Hum Pathol 1996; 27: 1377-1381.

20. MURPHY,J.P. AND WEIN, A.J: Experience in the treatment of prostatic carcinoma with Cyproterona acetate.J. Urol. 1973; 109: 68-70.

21. OESERLING,J.E.; EPSTEIN,J.I. AND WALSH,P.Q: The inability of adrenal Androgens to stimulate the Adult human Prostate: An autopsy evaluation of men with hypogonathopic hypogonadism and panhypopituitarism. J. Urol. 1986: 136: 1030-1034.

22. PAULSON, D.F: Pronostic factors in Androgen-Independent Prostatic Carcinoma. AUA update series. 1983. Leson 17 Vol.II.

23. PETERS,C.A. AND WALSH,P.C: The effect of Nafarelin acetate a luteinizing-hormone-releasing hormone agonist, on Bening Prostatic Hyperplasia. N. Engl.J. Med.1987; 317: 599-604.

24. PINAULT, S. ; TÉTU,B.; GAGMON,J.; MONFETTE.G.;DUPONT,A. AND LABRIE,F: Transrectal Ultrasound Evaluations of local Prostatic Cancer in patients treated with LH-RH agonist and in combinations with Flutamide Urology 1992;39: 254-257.

25. RAYNAUD,J.; BONNE,C.; MOGUILEWSKY,M.;LEFEBRE,F.;BELANGER,A. AND FABRIE,F: The pure Antiandrogen RU 23908 (Anandron) a candidate of choice for the combined antihormonal Treatment of Prostatic Cancer. The Prostate 1984; 5: 299-311.

26. SCHULMAN,C.C.AND SASSINE,A.M: Bloqueo Hormonal neoadyuvante antes de la prostatetomía radical. Eur Urol 1995. Vol II. Número 1. Febrero 18-23 ( Edición Española)

27. SHALLY, A.V.; ARIMURA,A.;KESTIN,A.J.;MATSUD,H.; BABE,Y.; REDDING,T.W.; NAIR,R.M.G.; DEBEJUK,L. AND WHITE,W.F: Gonadrotopin-releasing hormone: one polypeptide regulates secretion of luteinizing hormone and follicule stimulating hormones. Science 1971; 173: 1036-1039.

28. SCHÖEDER,F.H: Metastasic Cancer of the Prostate managed with Buserelin versus Buserelin plus cyyproterone acetate.J. Urol. 1987; 137: 912-916.

29. SCHRÖDER, F.H: Adjuvant Endocrine Treatment of Prostatic Cancer. Ebu, European Board of Urology 1993. Volume 2. Number 24.

30. SMITH,D.M. AND MURPHY,W.M: Histologic Changes in Prostate Carcinomas Treated with Leuprolide ( Luteinizing Hormone-Releasing Hormone Effect). Cancer 1994; 73: 1472-7.

31. TETU,B.; SRIGLEY,J.R.;BOIVIN,J.C.;DUPONT,A.; MONFETTE,G.; PINAULT,S. AND FABRIE,F: Effect of combination endocrine therapy (LH-RH Agonist and flutamide) on normal prostate and prostatic Adenocarcinoma. Am.J. Sur. Pathol. 1991; 15(2) 111-120.

32. TOLIS,G.;ACKMAN,D.;STELLO,A.;MEHTA,A; LABRIE,F.; FAZECKAS,A.T.; COMARU-SCHALLY,A.M. AND SCHALLY, A.V: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.Medical Sciences 1982; 79: 1658-1662.

33. TRACHTENBERG,J. AND WALSH,P.C: Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J. Uro. 1982; 127: 466-471.

34. VAN DER KWAST,T.H.; DE WINTER, J.A.R.AND TRAPMAN, J: Androgen Receptor Expression in Human Prostate Cancer, Journal of Urologic Pathology1995, Volume 3.

35. VILLAVICENCIO,H.; LAGUNA,J.; Y PONCE DE LEÓN, J: Impacto clínico del tratamiento neoadyuvante a prostatectomia radical en el cancer prostático localmente avanzado. Actas Urol Esp. 18 ( Supl.) : 404-408,1994.

36. VILLAVICENCIO,H.; ALGABA,F.; LAGUNA,J.; PONCE DE LEÓN, X: Estudio anatomo-patológico completo de 26 prostatectomías radicales, estadio C clínico.

37.WOJNO,D.J.AND EPSTEIN J.I: The utility of basal Cell-Specific Anti-Cytokeratin Antibody (34BE12) in the Diagnosis of Prostate Cancer. Areview of 228 Cases. Am J. Surg. Pathol. 1995; 19 (3): 251-260.

38. ZUNGRI.E: Agonistes LH-RH: utilité dans le traitement du cancer de la prostate au stade avancé. Encyclopédie Médico-Chirurgicale 1986; 18560A 10.



Ana de la Fuente, M.D. Servicio de Anatomía Patológica, Centro Médico POVISA. Oviedo, España.
Copyright © 1997. Reservados todos los derechos.